{"name":"Annovis Bio","slug":"annovis","ticker":"ANVS","exchange":"NYSE","domain":"annovisbio.com","description":"Annovis Bio is a clinical-stage biotech company focused on neuroscience. The company's top drugs include ANVS401, ANVS407, and ANVS501. Annovis Bio is developing treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS).","hq":"Malvern, PA","founded":0,"employees":"","ceo":"Maria Maccecchini, Ph.D.","sector":"Neuroscience / Clinical-Stage Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":25215607,"netIncome":-28854197,"cash":21081625,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ANVS401 patent cliff ($0.0B at risk)","drug":"ANVS401","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"ANVS407 patent cliff ($0.0B at risk)","drug":"ANVS407","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"ANVS501 patent cliff ($0.0B at risk)","drug":"ANVS501","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Posiphen","genericName":"Posiphen","slug":"posiphen","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"buntanetap/posiphen","genericName":"buntanetap/posiphen","slug":"buntanetap-posiphen","indication":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)","status":"phase_3"}]}],"pipeline":[{"name":"Posiphen","genericName":"Posiphen","slug":"posiphen","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"buntanetap/posiphen","genericName":"buntanetap/posiphen","slug":"buntanetap-posiphen","phase":"phase_3","mechanism":"Buntanetap/posiphen inhibits translation of amyloid precursor protein (APP) and tau, reducing production of amyloid-beta and tau pathology in the brain.","indications":["Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Annovis Bio Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Annovis Bio reported its fourth quarter and full year 2023 financial results, with a net loss of $23.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"trial","headline":"Annovis Bio Announces Positive Topline Results from Phase 2 Clinical Trial of ANVS401 in Alzheimer's Disease","summary":"Annovis Bio announced positive topline results from its Phase 2 clinical trial of ANVS401 in Alzheimer's disease.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"deal","headline":"Annovis Bio Enters into Agreement with University of California, San Francisco to Develop New Therapeutic Candidates","summary":"Annovis Bio entered into an agreement with the University of California, San Francisco to develop new therapeutic candidates.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tNTFOcWJucGZyeG4ydkFFZlVCOUdEMTlXaFFGRkdxZzlMUlVFRWZRV25Xc2VEb0NtRGhxN1p2MG9SaUY3TVNGMzFyMmMxeEl6Z3RZRWxYa0F2dw?oc=5","date":"2026-04-01","type":"pipeline","source":"TradingView","summary":"ANVS Stock Price and Chart — NYSE:ANVS - TradingView","headline":"ANVS Stock Price and Chart — NYSE:ANVS","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1GRHVtaE44aVE3dnM5NmM2UjNZX3h2NmZXYmNVU25heUQ3VmM1czhfcTZ6TUR1dmJQMC10RzN2aUQtRFl4Mjl0QnR4SFhUWmxGaWZPVlAtUDhVMExRcG1Ka0o4RkI2OXQ0ZFZnb2Zn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan","headline":"If You Invested $1,000 in Annovis Bio Inc (ANVS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5VLUQyWnctTjdJeGRBbmllb2FtTFZ6eDhhVnpiMF9HeUs5M0g0b25TWjEyMDZPREVtaGhDZm1rWk96eEFmVXI3SU5NdkxPUE80RjJN?oc=5","date":"2026-03-19","type":"pipeline","source":"firstwordpharma.com","summary":"Annovis adopts Apple Watch for Parkinson's symptom monitoring - firstwordpharma.com","headline":"Annovis adopts Apple Watch for Parkinson's symptom monitoring","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxON05VaDhJNmVRcE5aQ2gtbi1rY2hDTnhiTko5SExPazgwVk43UzJMN1V1cmt4eVo5enVHNDJjdXhMRnI2ZFd6bjB6cnl6aGtpN2lIUkptbGNvZ0p0N0otRXNLSDlPaGNpc2NWXzhyZVFiNjROOE04c2pFMUdfQlpuUlVzeWFFTzJieXRzZHVfcF9QT1BRek9qZTE1ajFPZ3d6YXdxcGlMSnZGd05TNmZxS0x3dl94YU5BMXhETGR4VnN1VmdJZ2Zz?oc=5","date":"2026-03-01","type":"trial","source":"AD HOC NEWS","summary":"Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS","headline":"Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze?","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNblpRcElYbjNiNjBtRGdTQ2tjbmlzODlKVEF5OFg2TVBxWUl3S3NhTEQ3V0VHLUN4MTZ0dHp0b3dybnZxQi1MRDJxZG1GWi1NZ2tINy0taTVfRmFEWjhGTnBwWHhQWHA2TUprUENJM01raG4yS0JSX3pSbE1odGNYdDhmclktWFE?oc=5","date":"2025-09-25","type":"pipeline","source":"Yahoo Finance","summary":"Annovis Appoints Mark Guerin as Chief Financial Officer - Yahoo Finance","headline":"Annovis Appoints Mark Guerin as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPdnVMTGt6WHhydGNISkIwSDVZekdtOVNwYU41RHMyQ1VZN0QxUDJRd1BzSnpiR1BXdGFWLWV4SjBzUjk0UVFLTUlObHY4d3BYcUhYb3VsTGhySFFoYU9UU0NhNTk4WUI0V21kZS0wdHJUMUVWcnpaeXJ2XzMtMHRsTW16dzRXYmswaER2Rk12a0pqZTlNc0V6SGJjSQ?oc=5","date":"2024-10-01","type":"pipeline","source":"Life Science Leader","summary":"Annovis Bio: Against The Grain In Alzheimer's Disease - Life Science Leader","headline":"Annovis Bio: Against The Grain In Alzheimer's Disease","sentiment":"neutral"}],"patents":[{"drugName":"ANVS401","drugSlug":"anvs401","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"ANVS407","drugSlug":"anvs407","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"ANVS501","drugSlug":"anvs501","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Roche Holding","Pfizer"],"therapeuticFocus":["Neurodegenerative Diseases","Alzheimer's Disease","Parkinson's Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":0,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":25215607,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-28854197,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":21081625,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}